These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Antispasticity medications. Nance PW; Young RR Phys Med Rehabil Clin N Am; 1999 May; 10(2):337-55, viii. PubMed ID: 10370935 [TBL] [Abstract][Full Text] [Related]
26. A phase IV observational multi-centre, open-label study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system. Prabhoo R; Keny S; Prabhoo T; Singh A; Rana R J Assoc Physicians India; 2011 Jan; 59():33-7. PubMed ID: 21751662 [TBL] [Abstract][Full Text] [Related]
27. A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin. Hennies OL J Int Med Res; 1981; 9(1):62-8. PubMed ID: 6451461 [TBL] [Abstract][Full Text] [Related]
28. [Intrathecal baclofen therapy and management of severe spasticity]. Naito Y Brain Nerve; 2014 Sep; 66(9):1049-55. PubMed ID: 25200576 [TBL] [Abstract][Full Text] [Related]
29. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population. Smith HS; Barton AE Am J Hosp Palliat Care; 2000; 17(1):50-8. PubMed ID: 11094920 [TBL] [Abstract][Full Text] [Related]
30. Dantrolene sodium: long-term effects in severe spasticity. Chyatte SB; Basmajian JV Arch Phys Med Rehabil; 1973 Jul; 54(7):311-5. PubMed ID: 4577936 [No Abstract] [Full Text] [Related]
31. Encephalopathy and hypotonia due to baclofen toxicity in a patient with end-stage renal disease. Ijaz M; Tariq H; Kashif M; Marquez JG Am J Case Rep; 2015 Apr; 16():232-5. PubMed ID: 25895118 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Otero-Romero S; Sastre-Garriga J; Comi G; Hartung HP; Soelberg Sørensen P; Thompson AJ; Vermersch P; Gold R; Montalban X Mult Scler; 2016 Oct; 22(11):1386-1396. PubMed ID: 27207462 [TBL] [Abstract][Full Text] [Related]
33. A review of intrathecal baclofen in the management of spasticity. Porter B Br J Nurs; 1997 Mar 13-26; 6(5):253-60, 262. PubMed ID: 9155275 [TBL] [Abstract][Full Text] [Related]
34. [Mydeton: a centrally acting muscle relaxant drug from Gedeon Richter LTD]. Kocsis P; Tarnawa I; Kovács G; Szombathelyi Z; Farkas S Acta Pharm Hung; 2002; 72(1):49-61. PubMed ID: 12426787 [TBL] [Abstract][Full Text] [Related]
35. Managing spasticity with drugs. Simon O; Yelnik AP Eur J Phys Rehabil Med; 2010 Sep; 46(3):401-10. PubMed ID: 20927006 [TBL] [Abstract][Full Text] [Related]
36. Treatment of spasticity with dantrolene sodium. Mayer N; Necomber SA; Herman R Am J Phys Med; 1973 Feb; 52(1):18-29. PubMed ID: 4685519 [No Abstract] [Full Text] [Related]
37. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. Albright AL; Gilmartin R; Swift D; Krach LE; Ivanhoe CB; McLaughlin JF J Neurosurg; 2003 Feb; 98(2):291-5. PubMed ID: 12593613 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. Taricco M; Pagliacci MC; Telaro E; Adone R Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680 [TBL] [Abstract][Full Text] [Related]